A strategic consulting firm has formed a new venture capital arm with offices based in Minneapolis and Shanghai, China. Alongside investments, the firm advises life science companies on strategic partnerships (manufacturers, distributors) in the China market by providing resources in the network. The firm’s first fund is predicted to close end of 2016. The firm is seeking five new investments within the next year, and typically makes $1M – $5M dollar investments per company in Series B and C rounds, but also considers Series A. The firm acts as co-investors while also helping companies seek additional investors for the round. The firm focuses on US and Canada based companies, though is open to companies on a global-level.
The firm is indication agnostic and open to technology in all sectors of life science – medical devices, therapeutics, diagnostics, and healthcare IT – while having the most experience in biotech/medtech. In terms of phase of development, the firm requires the company to at least have a prototype, and for therapeutics to be in clinical trials, preferably in Series B. The firm will also look at on-the-market products as well as lab equipment and drug development enabling technology.
The firm requires the company to be in Series A, B, or C. The firm prefers the company to have or seek to have their technology in the China market.
If you are interested in more information about this investor and other investors tracked by LSN, please email firstname.lastname@example.org